These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9704047)

  • 1. Ultrastructural changes of neutrophils following IL-2 treatment in vivo.
    Nano R; Capelli E; Barni S; Gerzeli G
    Ann N Y Acad Sci; 1997 Dec; 832():194-9. PubMed ID: 9704047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidence.
    Capelli E; Barni S; Vaccarone R; Fortis C; Nano R
    Anticancer Res; 1996; 16(4A):1775-80. PubMed ID: 8712700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil activation, vascular leak toxicity, and cytolysis during interleukin-2 infusion in human cancer.
    Carey PD; Wakefield CH; Guillou PJ
    Surgery; 1997 Nov; 122(5):918-26. PubMed ID: 9369892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
    Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
    Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
    Janssen RA; Sleijfer DT; Heijn AA; Mulder NH; The TH; de Leij L
    Br J Cancer; 1992 Dec; 66(6):1177-9. PubMed ID: 1457361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.
    Jones M; Philip T; Palmer P; von der Maase H; Vinke J; Elson P; Franks CR; Selby P
    Cancer Biother; 1993; 8(4):275-88. PubMed ID: 7804369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
    Ubhi SS; Horsburgh T; Veitch PS; Bell PR
    Anticancer Res; 1991; 11(6):2059-62. PubMed ID: 1776840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients.
    Sculier JP; Body JJ; Donnadieu N; Nejai S; Glibert F; Raymakers N; Paesmans M
    Cancer Chemother Pharmacol; 1990; 26(5):355-8. PubMed ID: 2208578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
    Baars JW; Hack CE; Wagstaff J; Eerenberg-Belmer AJ; Wolbink GJ; Thijs LG; Strack van Schijndel RJ; van der Vall HL; Pinedo HM
    Br J Cancer; 1992 Jan; 65(1):96-101. PubMed ID: 1733448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y; Tazaki H; Umeda T; Marumo K
    Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The release of interleukin-8 during intravenous bolus treatment with interleukin-2.
    Baars JW; Wolbink GJ; Hart MH; Hack CE; Eerenberg-Belmer AJ; Pinedo HM; Wagstaff J
    Ann Oncol; 1994 Dec; 5(10):929-34. PubMed ID: 7696165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
    Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S2-6. PubMed ID: 9457385
    [No Abstract]   [Full Text] [Related]  

  • 20. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
    Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.